Skip to main content

Table 2 Summary of study findings NOACs vs. VKA

From: Effectiveness and safety of vitamin K antagonists and new anticoagulants in the prevention of thromboembolism in atrial fibrillation in older adults – a systematic review of reviews and the development of recommendations to reduce inappropriate prescribing

  N studies Effect- model Effect measure Stroke/SE Ischemic stroke Haemorrhagic stroke Mortality Major bleeding Intracranial bleeding Gastrointestinal bleeding Myocardial infarction
Adam et al. 2012 [31] 3 REM RR Not stated 0.89 (0.78–1.02) 0.48 (0.36–0.62) 0.8 (0.82–0.96) Not stated Not stated Not stated Not stated
Baker et al.2012 [53] 4 REM RR 0.797 (99% CI 0.695–0.914) 0.880 (99% CI 0.742–1.044) 0.445 (99% CI 0.269–0.768) RR: 0.874 (99% CI 0.803–0.974) 0.878 (99% CI 0.664–1.160) Not stated 1.254 (99% CI 0.827–1.901) Not stated
Briceno et al. [29] 5 REM OR 0.84 (0.72–0.97) subgroup >75 years: 0.77 (0.68–0.87) Not stated Not stated 0.89 (0.84–0.94) 0.794 (0.647–0.973) Not stated Not stated Not stated
Capodanno et al. 2013 [47] 3 REM OR 0.82 (0.74–0.91) 0.93 (0.82–1.05) 0.44 (0.30–0.66) 0.88 (0.82–0.95) 0.85 (0.69–1.05) 0.46 (0.38–0.55) 1.68 (1.03–2.72) 0.99 (0.71–1.38)
Dogliotti et al. 2013 [48] 5 REM RR 0.82 (0.69–0.98) 0.87 (0.72–1.06) 0.49 (0.35–0.70) 0.91 (0.85–0.96) 0.84 (0.70–1.00) Not stated Not stated Not stated
Holster et al. 2013 [33] 8 REM OR Not stated Not stated Not stated Not stated 0.93 (0.75–1.16) Not stated 1.21 (0.91–1.61) Not stated
Jia et al. [54] 5 REM RR 0.86 (0.75–0.99)
high dose 0.80 (0.71–0.91)
low dose 1.03 (0.84–1.27)
high dose 0.93 (0.84–1.03)
low dose 1.13 (1.14–1.49)
high dose 0.50 (0.41–0.62)
low dose 0.33 (0.23–0.46)
high dose 0.90 (0.85–0.95)
low dose 0.89 (0.83–0.96)
0.78 (0.64–0.94)
high dose 0.86 (0.74–0.99)
low dose 0.63 (0.38–1.04)
high dose 0.48 (0.41–0.56)
low dose 0.31 (0.24–0.41)
high dose 1.24 (1.10–1.39)
low dose 0.52 (0.19–1.00)
high dose 0.97 (0.85–1.11)
low dose 1.25 (1.04–1.50)
Lega et al. [30] 3 REM RR >75 years: 0.77 (0.67–0.89)
<75 years: 0.83 (0.71–0.96)
Not stated Not stated Not stated >75 years: 0.90 (0.82–1.00)
<75 years: 0.73 (0.65–0.81)
Not stated Not stated Not stated
Liew et al. 2014 [49] 4 REM RR Not stated Not stated Not stated 0.89 (0.85–0.94) Not stated 0.42 (0.34–0.53) Not stated Not stated
Miller et al. 2012 [50] 3 REM RR 0.78 (0.67–0.92) 0.87 (0.77–0.99) 0.45 (0.31–0.68) 0.88 (0.82–0.95) 0.88 (0.71–1.09) 0.49 (0.36–0.66) 1.25 (0.91–1.72) 0.96 (0.73–1.26)
Providência et al. 2014 [51] 7 REM RR 0.84 (0.74–0.95) 0.97 (0.83–1.14) Not stated 0.90 (0.86–0.95) 0.79 (0.67–0.93) 0.49 (0.37–0.63) 1.07 (0.86–1.34) 1.01 (0.83–1.24)
Rong et al. 2015 [66] 4 REM RR Not stated Not stated Not stated Not stated 0.77 (0.63–0.95)
high dose: 0.86 (0.73–1.01)
low dose: 0.63 (0.38–1.04)
0.42 (0.34–0.52)
high dose: 0.48 (0.39–0.59)
low dose: 0.31 (0.24–0.41)
1.10 (0.86–1.41)
high dose: 1.25 (0.99–1.57)
low dose: 0.87 (0.54–1.40)
Not stated
Ruff et al. 2014 [28] 4 REM RR 0.81 (0.73–0.91) 0.92 (0.83–1.02) 0.49 (0.38–0.64) 0.90 (0.85–0.95) 0.86 (0.73–1.00) 0.48 (0.39–0.59) 1.25 (1.,01–1.55) 0.97 (0.78–1.20)
Sardar et al. 2013 [64] 3 REM OR 0.85 (0.74–0.99) Not stated 0.37 (0.19–0.72) 0.90 (0.79–1.02) 0.84 (0.69–1.03) 0.42 (0.25–0.70) 1.17 (0.76–1.80) Not stated
Senoo et al. [65] 3 REM RR 0.45 (0.24–0.85) Not stated Not stated Not stated 0.66 (0.29–1.47) 0.46 (0.18–1.16) 0.52 (0.25–1.08) Not stated
Testa et al. 2012 [52] 3 FEM OR 0.92 (0.83–1.02) 0.93 (0.83–1.05) 0.43 (0.34–0.55) 0.90 (0.84–0.96) EC 0.98 (0.91–1.07) Not stated Not stated 1.03 (0.89–1.20)
NOACs vs. warfarin or ASA or VKA vs. NOACs/PAI (not included in analysis)
 Chatterje et al. 2013 [63] 6 REM OR Not stated Not stated Not stated Not stated Not stated OR 0.49 (0.36–0.65) Not stated Not stated
 Sardar et al. 2014 [32] 4 REM OR 0.65 (0.48–0.87) Not stated Not stated Not stated 0.82 (0.58–1.16) Not stated Not stated Not stated
 Agarwal et al. 2012 8 FEM RR 1.44 (1.18–1.78) Not stated Not stated Not stated Not stated Not stated Not stated Not stated
  1. 95% Confidence intervals are provided unless otherwise reported
  2. FEM fixed effect model, OR odds ratio, REM random effect model, RR relative risk